CVS Health raised its full-year profit forecast on Thursday and said it plans to exit the market for Obamacare health ...

The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per ...

CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my ...

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...

CVS Health's revenues increased to $94.6 billion in the first quarter, an increase of 7% compared to the prior year.

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...

CVS Health ( NYSE: CVS) on Thursday announced plans to discontinue operations in the individual health insurance business, ...

CVS Health shares powered 9% higher before the bell Thursday after the pharmacy and healthcare giant's first-quarter results ...

CVS Health hiked its 2025 forecast above Wall Street’s expectations after improving Medicare benefits contributed to a better ...

CVS Health raised its full-year profit forecast on Thursday following strong performance across its businesses, signaling ...

CVS Health recorded a net income of $1.8 billion in the first quarter of 2025, up from $1.1 billion during the same period last year.

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.